STOCK TITAN

Tempus to Present at 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Tempus AI (NASDAQ: TEM) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 13-16, 2025, in San Francisco. The company's involvement includes two key events:

1. A presentation and Q&A session with investors led by Founder and CEO Eric Lefkofsky on Monday, January 13

2. A panel discussion on Policy Outlook for Artificial Intelligence in Healthcare & Diagnostics featuring Chief Scientific Officer Kate Sasser on Wednesday, January 15

The company will provide a live webcast option for accessing the January 13 presentation. Tempus AI specializes in leveraging artificial intelligence to enhance precision medicine and improve patient care outcomes.

Tempus AI (NASDAQ: TEM) ha annunciato la sua partecipazione al 43° Convegno Annuale J.P. Morgan sulla Sanità, in programma dal 13 al 16 gennaio 2025 a San Francisco. Il coinvolgimento dell'azienda prevede due eventi chiave:

1. Una presentazione e una sessione di domande e risposte con gli investitori condotta da Fondatore e CEO Eric Lefkofsky lunedì 13 gennaio

2. Una tavola rotonda sul Futuro delle Politiche per l'Intelligenza Artificiale nella Sanità e nei Diagnostici con la Chief Scientific Officer Kate Sasser mercoledì 15 gennaio

L'azienda offrirà un'opzione di webcast in diretta per accedere alla presentazione del 13 gennaio. Tempus AI si specializza nell'utilizzo dell'intelligenza artificiale per migliorare la medicina di precisione e gli esiti delle cure per i pazienti.

Tempus AI (NASDAQ: TEM) ha anunciado su participación en la 43ª Conferencia Anual J.P. Morgan de Salud, programada del 13 al 16 de enero de 2025 en San Francisco. La participación de la empresa incluye dos eventos clave:

1. Una presentación y sesión de preguntas y respuestas con inversionistas a cargo de Fundador y CEO Eric Lefkofsky el lunes 13 de enero

2. Un panel de discusión sobre Perspectivas de Políticas para la Inteligencia Artificial en Salud y Diagnósticos con la Chief Scientific Officer Kate Sasser el miércoles 15 de enero

La empresa ofrecerá una opción de webcast en vivo para acceder a la presentación del 13 de enero. Tempus AI se especializa en aprovechar la inteligencia artificial para mejorar la medicina de precisión y los resultados en la atención del paciente.

템퍼스 AI (NASDAQ: TEM)는 2025년 1월 13일부터 16일까지 샌프란시스코에서 열리는 제43회 연례 J.P. 모건 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 참여에는 두 가지 주요 이벤트가 포함됩니다:

1. 설립자이자 CEO인 에릭 레프코프스키가 이끌어가는 투자자와의 발표 및 질문과 답변 세션이 1월 13일 월요일에 진행됩니다.

2. 의료 및 진단 분야의 인공지능 정책 전망에 대한 패널 토론이 1월 15일 수요일에 Chief Scientific Officer인 케이트 샐서와 함께 진행됩니다.

회사는 1월 13일 발표를 시청할 수 있는 라이브 웹캐스트 옵션을 제공할 것입니다. 템퍼스 AI는 인공지능을 활용하여 정밀 의학을 개선하고 환자 치료 결과를 향상시키는 데 전문화된 회사입니다.

Tempus AI (NASDAQ: TEM) a annoncé sa participation à la 43ème Conférence Annuelle J.P. Morgan sur la Santé, prévue du 13 au 16 janvier 2025 à San Francisco. L'implication de l'entreprise comprend deux événements clés :

1. Une présentation et une session de questions-réponses avec des investisseurs dirigée par le Fondateur et CEO Eric Lefkofsky le lundi 13 janvier

2. Un panel de discussion sur Les Perspectives Politiques pour l'Intelligence Artificielle dans le Secteur de la Santé et du Diagnostic avec la Chief Scientific Officer Kate Sasser, le mercredi 15 janvier

L'entreprise proposera une option de webdiffusion en direct pour accéder à la présentation du 13 janvier. Tempus AI se spécialise dans l'utilisation de l'intelligence artificielle pour améliorer la médecine de précision et les résultats des soins aux patients.

Tempus AI (NASDAQ: TEM) hat seine Teilnahme an der 43. jährlichen J.P. Morgan Gesundheitskonferenz angekündigt, die vom 13. bis 16. Januar 2025 in San Francisco stattfinden wird. Die Beteiligung des Unternehmens umfasst zwei zentrale Veranstaltungen:

1. Eine Präsentation und eine Frage-Antwort-Runde mit Investoren, geleitet von Gründer und CEO Eric Lefkofsky, am Montag, den 13. Januar

2. Eine Podiumsdiskussion über Politikperspektiven zur Künstlichen Intelligenz im Gesundheitswesen und in der Diagnostik, an der die Chief Scientific Officer Kate Sasser am Mittwoch, den 15. Januar, teilnehmen wird.

Das Unternehmen wird eine Live-Webcast-Option anbieten, um auf die Präsentation vom 13. Januar zuzugreifen. Tempus AI hat sich darauf spezialisiert, Künstliche Intelligenz zu nutzen, um die Präzisionsmedizin zu verbessern und die Behandlungsergebnisse für Patienten zu optimieren.

Positive
  • None.
Negative
  • None.

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the 43rd Annual J.P. Morgan Healthcare on January 13-16, 2025, in San Francisco, CA.

  • Company Presentation | Tempus Founder and CEO, Eric Lefkofsky, will deliver a presentation and host a Q&A with the investment community at the conference on Monday, January 13.
  • Panel with Chief Scientific Officer, Kate Sasser | Policy Outlook for Artificial Intelligence in Healthcare & Diagnostics on Wednesday, January 15.

Alternatively, the company’s presentation on January 13 can be accessed via live webcast here.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding Tempus’ and its employee’s potential future speaking engagements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

Erin Carron

media@tempus.com

773-612-4414

Source: Tempus AI, Inc.

FAQ

When is Tempus (TEM) presenting at the 2025 J.P. Morgan Healthcare Conference?

Tempus (TEM) will present on Monday, January 13, 2025, with CEO Eric Lefkofsky delivering a presentation and hosting a Q&A session.

What topics will Tempus (TEM) discuss at the 2025 J.P. Morgan Healthcare Conference?

Tempus will discuss AI in healthcare, precision medicine, and policy outlook for AI in healthcare & diagnostics through a presentation and panel discussion.

How can investors access Tempus's (TEM) presentation at the J.P. Morgan Healthcare Conference?

Investors can access Tempus's January 13 presentation via a live webcast provided by the company.

What role will Tempus's (TEM) Chief Scientific Officer play at the J.P. Morgan Healthcare Conference?

Chief Scientific Officer Kate Sasser will participate in a panel discussion about Policy Outlook for Artificial Intelligence in Healthcare & Diagnostics on January 15, 2025.

Tempus AI, Inc.

NASDAQ:TEM

TEM Rankings

TEM Latest News

TEM Stock Data

5.91B
64.61M
57.56%
30.7%
3.9%
Health Information Services
Services-computer Programming, Data Processing, Etc.
Link
United States of America
CHICAGO